| Year |
Citation |
Score |
| 2022 |
McLemore AF, Hou HA, Meyer BS, Lam NB, Ward GA, Aldrich AL, Rodrigues MA, Vedder A, Zhang L, Padron E, Vincelette ND, Sallman DA, Abdel-Wahab O, List AF, McGraw KL. Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS-STING-NLRP3 axis in Myelodysplastic syndromes. Jci Insight. PMID 35788117 DOI: 10.1172/jci.insight.159430 |
0.469 |
|
| 2022 |
Shin TH, Zhou Y, Chen S, Cordes S, Grice MZ, Fan X, Lee BC, AlJanahi AA, Hong SG, Vaughan KL, Mattison JA, Kohama SG, Fabre MA, Uchida N, Demirci S, ... ... McGraw KL, et al. Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions. Blood. PMID 35714307 DOI: 10.1182/blood.2021014875 |
0.383 |
|
| 2021 |
Wang C, McGraw KL, McLemore AF, Komrokji R, Basiorka AA, Al Ali N, Lancet JE, Padron E, Kosmider O, Fontenay M, Fenaux P, List AF, Sallman DA. Dual pyroptotic biomarkers predict erythroid response in lower risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica. PMID 34320786 DOI: 10.3324/haematol.2021.278855 |
0.419 |
|
| 2021 |
Ward GA, McGraw KL, Abbas-Aghababazadeh F, Meyer BS, McLemore AF, Vincelette ND, Lam NB, Aldrich AL, Al Ali NH, Padron E, Pinilla-Ibarz J, Masala E, Santini V, Kosmider O, Fontenay M, et al. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Advances. 5: 2216-2228. PMID 33890980 DOI: 10.1182/bloodadvances.2020003475 |
0.462 |
|
| 2021 |
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, et al. Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002341. PMID 33449813 DOI: 10.1200/JCO.20.02341 |
0.436 |
|
| 2021 |
List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, et al. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001691. PMID 33439748 DOI: 10.1200/JCO.20.01691 |
0.466 |
|
| 2020 |
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. PMID 32730593 DOI: 10.1182/Blood.2020006158 |
0.552 |
|
| 2020 |
Nguyen L, Zhang X, Roberts E, Yun S, McGraw K, Abraham I, Song J, Braswell D, Qin D, Sallman DA, Lancet JE, List AF, Moscinski LC, Padron E, Zhang L. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated versus acute myeloid leukemia with myelodysplasia-related changes with mutated . Leukemia & Lymphoma. 1-11. PMID 32091281 DOI: 10.1080/10428194.2020.1723016 |
0.525 |
|
| 2019 |
McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, et al. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Advances. 3: 3579-3589. PMID 31738830 DOI: 10.1182/Bloodadvances.2019000922 |
0.568 |
|
| 2019 |
Sundaravel S, Kuo WL, Jeong JJ, Choudhary GS, Gordon-Mitchell S, Liu H, Bhagat TD, McGraw KL, Gurbuxani S, List AF, Verma A, Wickrema A. Loss of function of DOCK4 in myelodysplastic syndromes stem cells is restored by inhibitors of DOCK4 signaling networks. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31308061 DOI: 10.1158/1078-0432.Ccr-19-0924 |
0.521 |
|
| 2019 |
Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leukemia Research. 81: 56-61. PMID 31030089 DOI: 10.1016/J.Leukres.2019.03.008 |
0.533 |
|
| 2019 |
Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, et al. Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis. Cancer Discovery. PMID 30944118 DOI: 10.1158/2159-8290.Cd-18-1138 |
0.497 |
|
| 2019 |
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore AF, McGraw K, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) Blood. 134: 676-676. DOI: 10.1182/Blood-2019-131055 |
0.474 |
|
| 2019 |
Balasis ME, Vedder A, Sun L, Quintana A, Dhawan A, Newman H, Merlevede J, McGraw K, Kruer T, Ben-Crentsil N, Painter JS, Droin N, Cluzeau T, Letson C, Wei S, et al. Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All-Trans retinoic Acid (ATRA) through the Transcription Factor CREB Blood. 134: 1692-1692. DOI: 10.1182/Blood-2019-128573 |
0.519 |
|
| 2019 |
List AF, Sun Z, Verma A, Bennett JM, McGraw K, Maciejewski JP, Komrokji RS, Wassenaar TR, Luger SM, Mattison RJ, Cheema PS, Altman JK, Claxton DF, Schiffer CA, Artz AS, et al. Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health Blood. 134: 842-842. DOI: 10.1182/Blood-2019-127274 |
0.465 |
|
| 2019 |
Ward GA, McGraw K, McLemore AF, Lam NB, Hou H, Meyer BS, List AF. Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes Blood. 134: 774-774. DOI: 10.1182/Blood-2019-122358 |
0.499 |
|
| 2018 |
Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, et al. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. The Lancet. Haematology. PMID 30072146 DOI: 10.1016/S2352-3026(18)30109-1 |
0.461 |
|
| 2018 |
McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. British Journal of Haematology. PMID 29359794 DOI: 10.1111/Bjh.15099 |
0.468 |
|
| 2018 |
Sallman DA, DeZern AE, Steensma DP, Sweet KL, Cluzeau T, Sekeres MA, Garcia-Manero G, Roboz GJ, McLemore AF, McGraw KL, Puskas J, Zhang L, Bhagat CK, Yao J, Al Ali N, et al. Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Blood. 132: 3091-3091. DOI: 10.1182/Blood-2018-99-119990 |
0.509 |
|
| 2018 |
McGraw KL, Cheng C, Chen YA, Hou H, Genovese G, Cluzeau T, Pellagatti A, Przychodzen B, Mallo M, Leonor A, Mohamedali AM, Ades L, Sallman DA, Padron E, Sokol L, et al. SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition Blood. 132: 107-107. DOI: 10.1182/Blood-2018-99-118747 |
0.568 |
|
| 2018 |
Ward GA, McGraw KL, McLemore AF, Abbas-Aghababazadeh F, Hou H, Trinh TL, Vincelette ND, Meyer BS, Onimus AH, Calescibetta A, Eksioglu EA, Wei S, List AF. Oxidized Mitochondrial DNA Is a Catalyst and Biomarker of Pyroptotic Cell Death in Myelodysplastic Syndromes Blood. 132: 3076-3076. DOI: 10.1182/Blood-2018-99-118493 |
0.533 |
|
| 2018 |
McLemore AF, McGraw KL, Hou H, Ward GA, Onimus AH, Vincelette ND, Rodrigues MA, Chaudhary N, Zhang L, Meyer BS, Eksioglu EA, Wei S, List AF. Genomic-DNA Exposed By Somatic Gene Mutations Engages the cGAS/STING Axis to License the NLRP3 Inflammasome in Myelodysplastic Syndromes Blood. 132: 3075-3075. DOI: 10.1182/Blood-2018-99-116929 |
0.532 |
|
| 2018 |
Sallman DA, DeZern A, Sweet K, Steensma DP, Cluzeau T, Sekeres M, Garcia-Manero G, Roboz G, McLemore A, McGraw K, Puskas J, Zhang L, Bhagat C, Graber A, Ali NHA, et al. Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct068 |
0.488 |
|
| 2017 |
Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski JP, Auberger P, Wei S, Fenaux P, Santini V, List A. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica. PMID 28983059 DOI: 10.3324/Haematol.2016.158857 |
0.545 |
|
| 2017 |
McGraw K, List A. Erythropoietin Receptor Signaling and Lipid Rafts. Vitamins and Hormones. 105: 79-100. PMID 28629526 DOI: 10.1016/Bs.Vh.2017.02.002 |
0.453 |
|
| 2017 |
Sallman DA, Amy M, Komrokji RS, McGraw K, Geyer SM, Eksioglu E, Ali NA, Lancet JE, Wei S, Padron E, List AF. Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype Blood. 130: 423-423. DOI: 10.1182/Blood.V130.Suppl_1.423.423 |
0.555 |
|
| 2016 |
Zhang L, McGraw KL, Sallman DA, List AF. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leukemia & Lymphoma. 1-14. PMID 27967292 DOI: 10.1080/10428194.2016.1266625 |
0.567 |
|
| 2016 |
Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, et al. The NLRP3 Inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. PMID 27737891 DOI: 10.1182/Blood-2016-07-730556 |
0.516 |
|
| 2016 |
Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 30: 2405-2409. PMID 27560106 DOI: 10.1038/Leu.2016.228 |
0.472 |
|
| 2016 |
Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Research. PMID 27197154 DOI: 10.1158/0008-5472.Can-15-1756 |
0.516 |
|
| 2016 |
McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. PMID 27081179 DOI: 10.3324/Haematol.2016.143214 |
0.528 |
|
| 2016 |
Mcgraw KL, Nguyen J, Alali N, Song J, Sallman D, Padron E, Lancet JE, Qin D, Epling-Burnette P, Moscinski LC, Komrokji RS, List AF, Zhang L. EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome Blood. 128: 4305-4305. DOI: 10.1182/Blood.V128.22.4305.4305 |
0.574 |
|
| 2016 |
Lancet JE, Komrokji RS, Sweet KL, Duong VH, McGraw KL, Zhang L, Nardelli LA, Ma Z, Reich RR, Padron E, List AF. Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS) Blood. 128: 3174-3174. DOI: 10.1182/Blood.V128.22.3174.3174 |
0.54 |
|
| 2016 |
List AF, Sun Z, Verma A, Bennett JM, McGraw KL, Nardelli LA, Maciejewski JP, Altman JK, Cheema P, Claxton DF, Komrokji RS, Luger S, Mattison R, Wassenaar T, Artz A, et al. Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health Blood. 128: 223-223. DOI: 10.1182/Blood.V128.22.223.223 |
0.544 |
|
| 2016 |
Basiorka AA, Ma Z, Mcgraw KL, Sallman D, Irvine BA, Al Ali NH, Padron E, Pinilla-Ibarz J, Komrokji RS, Sokol L, Wei S, List AF. NLRP3 Inflammasome-Derived ASC Specks Are a Diagnostic Biomarker for Myelodysplastic Syndromes (MDS) Blood. 128: 2005-2005. DOI: 10.1182/Blood.V128.22.2005.2005 |
0.477 |
|
| 2016 |
McGraw K, Cheng C, Chen A, Genovese G, Cluzeau T, Lin H, Przychodzen B, Mallo M, Arenillas L, Mohamedali A, Ades L, Basiorka A, Irvine B, Sallman D, Padron E, et al. Abstract 2570: Identification of genetic polymorphisms associated with myelodysplastic syndromes by genome-wide association study Cancer Research. 76: 2570-2570. DOI: 10.1158/1538-7445.Am2016-2570 |
0.526 |
|
| 2015 |
Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, et al. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America. 112: E6359-E6368. PMID 26578796 DOI: 10.1073/Pnas.1516394112 |
0.542 |
|
| 2015 |
Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. PMID 26514544 DOI: 10.1038/leu.2015.304 |
0.317 |
|
| 2015 |
McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. PMID 26416416 DOI: 10.18632/Oncotarget.5255 |
0.509 |
|
| 2015 |
Pellagatti A, Roy S, Di Genua C, Burns A, McGraw K, Valletta S, Larrayoz MJ, Fernandez-Mercado M, Mason J, Killick S, Mecucci C, Calasanz MJ, List A, Schuh A, Boultwood J. Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia. PMID 25991409 DOI: 10.1038/Leu.2015.129 |
0.506 |
|
| 2015 |
McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, et al. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer Journal. 5: e291. PMID 25768405 DOI: 10.1038/bcj.2015.11 |
0.463 |
|
| 2015 |
Johnny N, McGraw KL, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes Blood. 126: 4121-4121. DOI: 10.1182/Blood.V126.23.4121.4121 |
0.553 |
|
| 2015 |
Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Mufti GJ, Maciejewski JP, Wei S, Fenaux P, Santini V, List AF. The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes Blood. 126: 355-355. DOI: 10.1182/Blood.V126.23.355.355 |
0.525 |
|
| 2015 |
Mian SA, Kulasekararaj AG, Kizilors A, McGraw KL, Kordasti S, Menzel S, Smith Ae, Perezabellan P, Sallman D, List AF, Mufti GJ. NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders Blood. 126: 1659-1659. DOI: 10.1182/Blood.V126.23.1659.1659 |
0.556 |
|
| 2015 |
Wei S, Eksioglu EA, Chen X, Cluzeau T, Basiorka A, Burnette A, Wei M, McGraw KL, Padron E, List AF. Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype Blood. 126: 144-144. DOI: 10.1182/Blood.V126.23.144.144 |
0.533 |
|
| 2015 |
Basiorka A, Mcgraw K, Eksioglu E, Chen X, Johnson J, Padron E, Komrokji R, Sokol L, Coll R, O'Neill L, Cooper M, Robertson A, Wei S, List A. 32 ACTIVATION OF REDOX-SENSITIVE INFLAMMASOMES UNDERLIES THE BIOLOGICAL PHENOTYPE OF MYELODYSPLASTIC SYNDROMES Leukemia Research. 39: S14. DOI: 10.1016/S0145-2126(15)30033-3 |
0.516 |
|
| 2015 |
Sallman D, Komrokji R, Vaupel C, Cluzeau T, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of Mutation Variant Allele Frequency on Phenotype, Outcomes, and Patient Management in Myelodysplastic Syndromes Clinical Lymphoma Myeloma and Leukemia. 15: S43-S44. DOI: 10.1016/J.Clml.2015.07.092 |
0.484 |
|
| 2015 |
Cluzeau T, McGraw KL, Basiorka AA, Irvine BA, Zhang L, Burnette PE, Rollison DE, Mallo M, Sokol L, Sole F, Karsan A, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in myelodysplastic syndromes Clinical Lymphoma Myeloma and Leukemia. 15: S42. DOI: 10.1016/J.Clml.2015.07.089 |
0.448 |
|
| 2014 |
McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. Plos One. 9: e114249. PMID 25469886 DOI: 10.1182/Blood.V124.21.4623.4623 |
0.523 |
|
| 2014 |
Eksioglu EA, Heider K, Rueter B, Burnette A, Wei M, McGraw K, Basiorka AA, Patel P, Lancet J, Komrokji R, List AF, Wei S. Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody Blood. 124: 4597-4597. DOI: 10.1182/Blood.V124.21.4597.4597 |
0.514 |
|
| 2014 |
Pellagatti A, Di Genua C, Roy S, Burns A, McGraw KL, Larrayoz MJ, Fernandez-Mercado M, Valletta S, Mason J, Killick S, Mecucci C, Calasanz MJ, List AF, Schuh A, Boultwood J. Targeted Re-Sequencing Analysis of 31 Genes Commonly Mutated in Myeloid Disorders in Serial Samples from Myelodysplastic Syndrome Patients with Disease Progression Blood. 124: 1901-1901. DOI: 10.1182/Blood.V124.21.1901.1901 |
0.51 |
|
| 2013 |
Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proceedings of the National Academy of Sciences of the United States of America. 110: 16127-32. PMID 24043769 DOI: 10.1073/Pnas.1311055110 |
0.563 |
|
| 2013 |
Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, LeBlanc F, Lagström S, Zhang D, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 122: 2453-9. PMID 23926297 DOI: 10.1182/Blood-2013-04-494930 |
0.564 |
|
| 2013 |
Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 121: 5068-77. PMID 23632888 DOI: 10.1182/Blood-2012-10-460170 |
0.513 |
|
| 2013 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. British Journal of Haematology. 160: 177-87. PMID 23157224 DOI: 10.1111/Bjh.12103 |
0.489 |
|
| 2013 |
Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 27: 897-906. PMID 23072779 DOI: 10.1038/Leu.2012.300 |
0.502 |
|
| 2013 |
Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 32: 1110-20. PMID 22525275 DOI: 10.1038/Onc.2012.139 |
0.544 |
|
| 2013 |
McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Recruitment of Epo-R into lipid rafts is dependent on Rac1 and RhoA GTPase activation. Plos One. DOI: 10.1371/Journal.Pone.0034477.G006 |
0.409 |
|
| 2013 |
Padron E, Painter J, Abdel-Wahab O, Kunigal S, Mailloux A, McGraw K, McDaniel J, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji R, List A, Epling-Burnette P. P-229 GM-CSF-dependent pSTAT5 Sensitivity is a Feature of chronic myelomonocytic leukemia and a therapeutic target Leukemia Research. 37: S126. DOI: 10.1016/S0145-2126(13)70276-5 |
0.309 |
|
| 2012 |
Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 120: 3048-57. PMID 22859607 DOI: 10.1182/Blood-2012-06-435297 |
0.513 |
|
| 2012 |
Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Research. 72: 4204-13. PMID 22761337 DOI: 10.1158/0008-5472.Can-12-0743 |
0.445 |
|
| 2012 |
Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 119: 6109-17. PMID 22553315 DOI: 10.1182/Blood-2011-12-397620 |
0.537 |
|
| 2012 |
McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Erythropoietin receptor signaling is membrane raft dependent. Plos One. 7: e34477. PMID 22509308 DOI: 10.1371/Journal.Pone.0034477 |
0.469 |
|
| 2012 |
Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. Journal of Hematology & Oncology. 5: 4. PMID 22390313 DOI: 10.1186/1756-8722-5-4 |
0.505 |
|
| 2012 |
Caceres G, Johnson J, McGraw KL, Basiorka AA, Liu K, Smith LJ, Daugherty FJ, Wei S, Komrokji RS, Zhang L, Littleton N, Wells RA, Sokol L, List AF. Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide Blood. 120: 920-920. DOI: 10.1182/Blood.V120.21.920.920 |
0.545 |
|
| 2012 |
Jerez A, Clemente MJ, Makishima H, Koskela HLM, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj AG, Afable MG, Husseinzadeh HD, Evans EP, Hosono N, LeBlanc F, Lagström S, et al. STAT3-Mutations Indicate the Presence of Subclinical Self-Reactive Cytotoxic T Cell Clones in Aplastic Anemia and Myelodysplastic Syndromes Blood. 120: 646-646. DOI: 10.1182/Blood.V120.21.646.646 |
0.561 |
|
| 2012 |
Padron E, Painter JS, Mailloux AW, McGraw KL, McDaniel JM, Bebbington C, Baer M, Yarranton G, Lancet JE, Komrokji RS, List AF, Epling-Burnette P. Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML) Blood. 120: 3793-3793. DOI: 10.1182/Blood.V120.21.3793.3793 |
0.473 |
|
| 2012 |
Basiorka AA, McGraw KL, Griner LN, Zhang L, De Ceuninck L, Caceres G, Sokol L, Komrokji RS, Wei S, Tavernier J, List AF. Lenalidomide Upregulates Erythropoietin Receptor Expression Through Inhibition of the E3-Ubiquitin Ligase Ring Finger Protein 41 (RNF41) Blood. 120: 3455-3455. DOI: 10.1182/Blood.V120.21.3455.3455 |
0.51 |
|
| 2012 |
McGraw KL, Zhang LM, Fulp W, Lin H, Jerez A, Basiorka AA, Caceres G, Rollison DE, Billingsley D, Kurtin SE, Sokol L, Epling-Burnette P, Mallo M, Sole F, Calasanz MJ, et al. Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome. Blood. 120: 2823-2823. DOI: 10.1182/Blood.V120.21.2823.2823 |
0.522 |
|
| 2011 |
Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, McGraw K, Clark JA, Sigua CA, Chen DT, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. British Journal of Haematology. 153: 24-32. PMID 21332710 DOI: 10.1111/J.1365-2141.2011.08581.X |
0.489 |
|
| 2011 |
Wei S, Chen X, Zhou J, Zhang L, Fortenbery NR, Rasche SS, McGraw K, Eksioglu EA, Epling-Burnette P, Djeu JY, Gabrilovich DI, List AF. Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC) Blood. 118: 788-788. DOI: 10.1182/Blood.V118.21.788.788 |
0.513 |
|
| 2011 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. A Mechanistic Rationale for the Use of Statins to Enhance JAK Inhibitor Therapy in MPNs Blood. 118: 2816-2816. DOI: 10.1182/Blood.V118.21.2816.2816 |
0.506 |
|
| 2011 |
Basiorka AA, McGraw K, Clark J, Caceres G, Johnson J, Hall L, Sokol L, Wei S, List AF. Lenalidomide Upregulates Erythropoietin Receptor Expression in Hematopoietic Progenitors by Modulating Receptor Turnover Blood. 118: 2382-2382. DOI: 10.1182/Blood.V118.21.2382.2382 |
0.51 |
|
| 2011 |
Wei S, Chen X, McGraw K, Zhou J, Burnette P, Wang H, Djeu J, Gabrilovich D, List A. 39 Myeloid-derived suppressor cells (MDSC) are effectors of bone marrow suppression in lower risk myelodysplastic syndromes (MDS) Leukemia Research. 35: S13. DOI: 10.1016/S0145-2126(11)70041-8 |
0.481 |
|
| 2010 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. Requirement of Lipid Raft Integrity for Signaling by JAK2-V617F Blood. 116: 4191-4191. DOI: 10.1182/Blood.V116.21.4191.4191 |
0.503 |
|
| Show low-probability matches. |